Neurology News

The FDA has approved UCB’s Zilbrysq for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.

Ajovy significantly reduced depression symptoms and monthly migraine days in a phase 4 study, with clinically meaningful improvements in disability outcomes, manufacturer Teva Pharmaceuticals announced in a press release.

Treatment with evobrutinib in continuous, twice-daily dosing provided the lowest relapse rate and highest arrest of clinical worsening after 5 years in those with relapsing multiple sclerosis, according to data presented at ECTRIMS 2023.

Women were nearly 50% more likely to develop depression after experiencing traumatic brain injury compared with men, according to a study presented at the American Society of Anesthesiologists annual meeting.

Treatment with ublituximab suppressed new lesion formations after 1 year while reducing thalamic volume loss and increasing T1 hypointense lesion volume compared with teriflunomide, according to data presented at ECTRIMS 2023.

In a cohort of individuals with relapsing multiple sclerosis, treatment with frexalimab significantly reduced new MRI lesions by week 24, according to a data presented at ECTRIMS 2023.

Increased physical activity may be associated with slower rates of macular ganglion cell-inner plexiform layer thinning, according to a study published in Investigative Ophthalmology & Visual Science.

Following 1 year of treatment with ozanimod, individuals with relapsing forms of multiple sclerosis saw functional and cognitive improvements as well as a reduction in MRI lesions, according to interim data presented at ECTRIMS 2023.

Those with relapsing forms of multiple sclerosis treated with ozanimod saw relapse-associated worsening and progression-independent relapse activity contributed similarly to disability progression, according to research from ECTRIMS 2023.

In relapsing forms of multiple sclerosis, fenebrutinib treatment led to reduction of lesion activity and resulted in higher penetration into cerebrospinal fluid at 12 weeks, according to research from ECTRIMS 2023.